CAMBRIDGE, Mass. & WILMINGTON, N.C.--(BUSINESS WIRE)--Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company, and Pharmaceutical Product Development, LLC (PPD), a leading global ...
The partnership leverages PPD’s pediatric clinical trial experience, regulatory knowledge, and site and pediatric patient networks, and Quotient’s expertise in pediatric formulation development, drug ...
North Carolina-based PPD has established a joint venture with Taijitu Biologics to develop and commercialize a technology platform for the discovery of first- and best-in-class monoclonal antibody ...
WASHINGTON (Reuters) - The hardest-to-treat form of drug-resistant tuberculosis is a growing threat in many parts of the world, but remains quite rare in the United States, U.S. government health ...
In the world of tuberculosis (TB) control, it is the worst-case scenario. Doctors in Mumbai, India, reported last month they are seeing a group of patients infected with what they called "totally drug ...
While the vaccines are products of private sector innovation, their evaluation has been firmly anchored in public science, with a large, independent Phase III clinical trial led, funded and sponsored ...
Tuberculosis, which kills around 1,000 people a day in India, has acquired a deadlier edge. A new entity, whic is ominously called Totally Drug-Resistant TB. While Iran first reported TDRTB cases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results